Beta Bionics



iLet Bionic Pancreas

The iLet Bionic Pancreas gives you time back with your patients

BETABIONICS.COM



Psychosocial Outcomes that matter

The iLet Bionic Pancreas helps reduce patients' diabetes distress

According to the American Diabetes Association, many type 1 patients suffer from diabetes distress and the emotional burden of living with and managing diabetes[1].

Do your patients feel:

- Overwhelmed by the demands of living with diabetes?
- Like they are "failing" with their diabetes?
- Worried about their risk of long-term complications?
- Frustrated that they can't predict or "control" diabetes from one day to the next?
- Guilty when their diabetes gets "off track"?
- Worried about going low so they take less insulin?

The iLet:

- Takes the burden away from the patient (user)[2]
- Reduces the anxiety[2]
- Lowers the fear of hypoglycemia[2]
- Requires minimal input from the user
- Continuously learns and adapts
- Determines 100% of insulin doses - no complicated math needed

The iLet Difference

During our clinical trial, adults on the iLet had a **lower fear of hypoglycemia**, had **less anxiety** about their diabetes and **felt less burden** than those on Standard of Care.[2] No other automated insulin delivery system on the market takes away the burden AND provides improved HbA1c results with less work.

The iLet Bionic Pancreas requires only one number to get your patient started - their weight

The iLet Bionic Pancreas makes it easy for you and your patients to get started

For Healthcare Providers

- ✔ Enter patient's weight
- ✔ Glucose targets can be adjusted

For Patients

- ✘ No carb counting*
- ✘ No blood glucose corrections
- ✘ No calculating boluses
- ✔ Fewer decisions about their treatment
- ✔ Connects to Dexcom G6 or G7
- ✔ Can be used with prefilled Fiasp® PumpCart® (insulin aspart) injection 100 units/mL cartridges

*User must be carb aware.

Who is the right patient for the iLet Bionic Pancreas?

More than 75% of patients with diabetes are not meeting their glycemic targets.[3] That's where the iLet can help!

Who is the iLet Bionic Pancreas Patient:

- Newly diagnosed with type 1 diabetes
- Overwhelmed with "being in charge" of their diabetes
- Using multiple daily injections (MDI)
- Frustrated with the work that their pump requires
- Struggling to reach their Time in Range or HbA1c goals
- Someone who doesn't want to focus too much on their diabetes
- Intimidated by diabetes technology and devices
- Suffering from diabetes burnout
- Challenges with carb counting

If this sounds like your patients, the iLet may be the right option.

What the iLet can do for your patient:

- Determines 100% of insulin doses
- Continuously learns and adapts to the individual instead of just reacting like other systems
- Fully autonomous meal, basal and correction algorithms that work together to keep the user in range
- Makes dose adjustments up to 288 times a day
- Completely eliminates manual correction doses
- Requires minimal input from user

The iLet Bionic Pancreas difference

Is the iLet Bionic Pancreas a hybrid closed loop system?
No, it's so much more.

Hybrid Closed Loop Systems

- **Healthcare Professional** determines and inputs basal rates, insulin-to-carb ratios, insulin action time and correction factors.
- **Users** make up to 180 diabetes decisions throughout the day.[3]
- **Hybrid Closed Loop** adjusts the basal rate based on the settings and provides limited correction doses.



So what is the iLet Bionic Pancreas?

It's an insulin delivery system managed by three algorithms that determine the right settings personalized to your patient.

iLet Bionic Pancreas

- **Healthcare professional** enters only the patient's weight
- **User** only makes a meal announcement
- **iLet** adjusts the basal rate throughout the day, doses corrections and determines meal doses based on the individual.



*User must be carb aware.

A day in the life with the iLet Bionic Pancreas

With diabetes, no two days are ever the same.

The iLet automatically adjusts to help keep your patient's glucose levels in control, even in the craziness of everyday life.



No Settings to Manage.
The iLet algorithms have it covered

The iLet makes 100% of the insulin dosing decisions, so your patients don't have to.

Basal Algorithm

- Determines basal insulin requirements
- Eliminates need for user to set basal rates
- Adapts continuously to changing insulin needs
- Develops and continuously updates basal rate profile for insulin delivery (288 automatically determined basal segments a day)

Corrections Algorithm

- Automatically adds insulin beyond basal insulin requirements
- Reduces insulin when needed to help protect against hypoglycemia
- Eliminates need for user to determine timing or size of correction doses
- Adapts continuously to changing needs
- Eliminates patient error regarding stacking (IOB)

Meal Announcement Algorithm

- Eliminates need for user to set or know insulin-to-carb ratios
- No carb counting. The iLet only needs an estimate of the carbs in the meal – Usual for me, More or Less
- Gives meal doses customized to the individual
- Automatically adjusts based on dosing history for similar previous meal announcements



iLet Reports

Healthcare providers can view all of their iLet Bionic Pancreas users' data in one online portal.

HCPs can review glucose and insulin overviews, time in range, meal announcements and insulin history.

HCP Portal

You can also review specific days on the Daily Views to pinpoint times of day or activities that may be leading to highs or lows.
https://report.betabionics.com

Glucose & Insulin Overview

Summarizes the user's CGM glucose and insulin doses over a 24-hour period for the selected date range.



Glucose Target, 24 hour

January 25, 2024 - January 26, 2024



Dexcom CGM Time in Range

Range in mg/dL



Dexcom CGM | Availability - 93.8%

Meal Announcements

Provides the number of meal announcements per day and the type announced - Usual for me, More or Less.



Meal Announcements Per Day - 3.4

More | Usual | Less

Glucose Summary

GMI	Average	SD	CV	Median
6.8%	146.2 mg/dL	42.8 mg/dL	29.3%	142 mg/dL

Insulin History

Updated 2024-Jan-26, 05:55 AM (GMT/UTC) • Body Weight - 220 lbs (100 kgs)

Usual Breakfast*	Usual Lunch*	Usual Dinner*	Total Daily Basal	Total Daily Dose
6.4 units	6.2 units	6.1 units	24.6 units	48.3 units

*Always refer to your iLet for the latest details

Daily views: (Page 2 of the iLet Report)

Provides daily readouts for the selected date range. Daily views include CGM metrics, meal announcements, insulin dosing and glucose target settings for each day.



The Bionic Pancreas Pivotal Trial is the largest randomized controlled trial evaluating the safety and efficacy of an AID system[5]

Primary outcome

- HbA1c at 13 weeks

Key secondary outcome

- Time CGM glucose < 54 mg/dl over 13 weeks

Other secondary end points

- Mean CGM
- Time in Range

No Exclusions for

- Recent episodes of severe hypoglycemia
- Hypoglycemia unawareness
- Recent episodes of DKA
- Recent hospitalization for dysglycemia
- Baseline HbA1c

Number of patients included in trial - 440

- iLet Bionic Pancreas (Humalog/Novolog and Fiasp) - 333
- Standard of Care - 107

Insulin therapy at enrollment and continued in Standard of Care group (with RT-CGM)

- MDI (34%)
- Insulin pump (31%)
- Hybrid closed loop system (35%)

Our pivotal study participant population was more diverse and representative of the US T1D community than any other pivotal trial of an AID system[5]

74%

White (non-Hispanic)

10%

Hispanic

10%

Black (non-Hispanic)

6%

Other or more than one race

Bionic Pancreas Pivotal Trial Results

The iLet Bionic Pancreas improved HbA1c more in those with a baseline HbA1c of >7%

Average HbA1c reduction in those with baseline HbA1c >7%[6,7]



The study was not designed to evaluate the effect of the iLet Bionic Pancreas in subgroups by baseline HbA1c. Individual user results may vary from the average values shown here.

Time in Range and HbA1c improved most in those with a higher baseline HbA1c[8]



Adults and children combined on iLet Bionic Pancreas with Humalog/Novolog. Values are Mean Baseline Adjusted Difference. The study was not designed to evaluate the effect of the iLet Bionic Pancreas in subgroups by baseline HbA1c. Individual user results may vary from the average values shown here. *n=iLet/Standard of Care.

Ready to have a patient GO BIONIC with the iLet Bionic Pancreas?

The iLet Bionic Pancreas can benefit your patients by:

- Removing calculations from their diabetes management
- Autonomously adapting to their insulin dosing needs
- Reducing their cognitive and emotional burden

To have a rep reach out to you, visit **betabionics.com/hcp** or call 1.855.745.3800.

HCP Website

HCP Resources

> *"The iLet was smarter than us, and it knew what to do . Let it do it!"*
>
> - DAVIDA KRUGER, MSN, APN-BC, BC-ADM

1. American Diabetes Association, (2021) ADA Mental Health Toolkit Handouts, Diabetes Distress.

2. Weissberg-Benchell J et al. Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes. Diabetes Technology and Therapeutics 2023; 25:705-717.

3. Hankosky ER et al. Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020. Diabetes Ther. 2023 Jun;14(6):967-975. doi: 10.1007/s13300-023-01399-0. Epub 2023 Apr 17. PMID: 37067668; PMCID: PMC10108820.

4. Erin Digitale Scopeblog Stanford. [2017-11-29]. New research keeps diabetics safer during sleep http://scopeblog.stanford.edu/2014/05/08/new-research-keeps-diabetics-safer-during-sleep/

5. Russell SJ et al. (2022) A Multicenter Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. The New England Journal of Medicine 2022; 387:1161–1172.

6. Kruger D et al. (2022) A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics 2022; 24:697–711.

7. Messer LH et al. (2022) Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6–17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial. Diabetes Technology and Therapeutics 2022; 24:712–725.

8. Russell SJ, Damiano ER, Calhoun P. Randomized Trial of a Bionic Pancreas in Type 1 Diabetes (response to Letters to the Editor). New England Journal of Medicine 2023; 388:380-382.

Safety Information

The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at www.betabionics.com/user-guides, or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to www.betabionics.com/safety. DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

Medical Disclaimer

This handout is for information only and is not a substitute for medical advice and/or services from a healthcare provider. All personal health care decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs.

Beta Bionics

Certified B Corporation

MM000025 Rev D 03/2024